ViaDerma, Inc. is a pharmaceutical company. The Company is engaged in the manufacture and sale of pharmaceutical related products in the United States of America. The Companyâ€™s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. The Company also has products in development in the fields: anti-aging skin care, pain management, hair-loss, and toenail fungus. Its products are based on a patent-pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Company utilizes a specific trade secret formulation system in the manufacture of all products. The Companyâ€™s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Companyâ€™s subsidiary is ViaDerma, II Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-22	0.000400 $	0.00%	26,092
26-06-18	0.000400 $	0.00%	4,000
26-06-17	0.000400 $	0.00%	7,551

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets Other stock markets 12:56:18 2026-06-22 EDT			5-day change	1st Jan Change
0.000400 ^USD	0.00%		0.00%	+100.00%

25-01-21	ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India	CI
24-08-13	ViaDerma, Inc. Announces Commencement of the Registration Process in Kenya, Namibia, and Tanzania for Strategic Expansion into East and Southern Africa	CI

Market Cap	6.31M 5.51M 5.1M 4.76M 8.93M 596M 9M 60.56M 23.56M 293M 23.67M 23.16M 1.02B	P/E 2015	10.7x	P/E 2016	-3.3x
Enterprise Value	6.6M 5.77M 5.34M 4.98M 9.35M 624M 9.42M 63.41M 24.67M 307M 24.79M 24.25M 1.07B	EV / Sales 2015	1.5x	EV / Sales 2016	3.63x
Free-Float	99%	Yield 2015 *	-	Yield 2016	-

25-01-21	ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India	CI
24-08-13	ViaDerma, Inc. Announces Commencement of the Registration Process in Kenya, Namibia, and Tanzania for Strategic Expansion into East and Southern Africa	CI
24-08-13	ViaDerma, Inc. Announces Shipment of 500,000 Units of its Product to Nigeria	CI
24-08-01	ViaDerma, Inc. Finalizes Distribution Agreements in Dubai	CI
23-03-16	ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product	CI
23-03-08	ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product	CI
22-09-15	ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products	CI
21-10-04	ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra	CI
21-06-24	ViaDerma, Inc. Provides Updates on Current Business Activities	CI
21-06-02	ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement	CI
21-05-13	ViaDerma, Inc. Nearing Initial Order from Large Hospital Network	CI
21-04-08	ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021	CI
21-01-21	ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States	CI

25-07-16	ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes	AQ
25-06-04	ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance	AQ
25-01-21	ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India	AQ
24-12-10	ViaDerma Announces Significant 2024 Achievements and International Expansion	AQ
24-10-03	ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth	AQ

ViaDerma, Inc. Stock

Stocks

VDRM

US92555K1016

Biotechnology & Medical Research

Valuation: ViaDerma, Inc.

Chart: ViaDerma, Inc.

Latest news : ViaDerma, Inc.

Press Releases: ViaDerma, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: ViaDerma, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.01
3 years	0		0.02
5 years	0		0.04
10 years	0		0.08

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIADERMA, INC.	0.00%	0.00%	+33.33%	-95.51%	493K
LONZA GROUP AG	+0.34%	+1.09%	-10.80%	-5.05%	43.13B
REVOLUTION MEDICINES, INC.	+1.00%	+2.97%	+311.61%	+560.03%	34.65B
BEONE MEDICINES AG	+0.07%	+0.84%	+5.03%	+45.48%	30.03B
IQVIA HOLDINGS INC.	-0.78%	-6.62%	+7.35%	-22.02%	28B
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	24.45B
ASCENDIS PHARMA A/S	-0.60%	+2.68%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-2.25%	-3.82%	+45.68%	+100.19%	13.14B
EUROFINS SCIENTIFIC SE	+1.54%	+0.16%	+6.65%	+8.89%	12.53B
IONIS PHARMACEUTICALS, INC.	+2.56%	+2.87%	+101.96%	+84.66%	12.25B
Average	+0.11%	+0.59%	+56.66%	+77.58%	21.25B
Weighted average by Cap.	+0.14%	+1.19%	+64.80%	+115.69%

	2015	2016
Net sales	192K 168K 155K 145K 272K 18.12M 274K 1.84M 717K 8.91M 720K 704K 30.95M	252K 220K 204K 190K 357K 23.81M 359K 2.42M 942K 11.71M 946K 926K 40.67M
Net income	27.12K 23.7K 21.92K 20.46K 38.41K 2.56M 38.69K 260K 101K 1.26M 102K 99.62K 4.38M	-122K -106K -98.45K -91.89K -173K -11.51M -174K -1.17M -455K -5.66M -457K -447K -19.66M
Net Debt	288K 252K 233K 217K 408K 27.24M 411K 2.77M 1.08M 13.39M 1.08M 1.06M 46.52M	297K 259K 240K 224K 420K 28.05M 423K 2.85M 1.11M 13.79M 1.11M 1.09M 47.9M